Poster Session D - Tuesday Morning
Category: IBD
Noa Krugliak Cleveland, MD
University of Chicago Medicine Inflammatory Bowel Disease Center
Chicago, Illinois
Study drug | Overall cohort, N | Mean (SD) unweighted study drug cost per patient, US$ |
Adalimumab | 1,178 | 36,045.07 (68,787.33) |
Infliximab | 1,046 | 22,469.39 (58,648.70) |
Vedolizumab | 311 | 12,717.97 (30,936.18) |
Ustekinumab | 129 | 33,339.80 (99,630.47) |
Study drug | Patients whose dose was escalated, N | Mean (SD) study drug cost per patient per month, US$ |
Adalimumab | 436 | 6,467.41 (2,936.65) |
Infliximab | 353 | 4,617.56 (4,119.17) |
Vedolizumab | 66 | 4,503.78 (1,817.49) |
Ustekinumab | 24 | 13,800.81 (6,587.90) |